Breaking News, Trials & Filings

Cantex’s Azeliragon Granted Orphan Drug Designation by FDA

Offers treatment options for patients with life-threatening cancer.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex Pharmaceuticals Inc.’s azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon’s two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively.   Cantex’s azeliragon is a well-tolerated compound, administered orally once a day, that inhibits the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters